title: The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline.
abstract: The standard treatment for patients with primary antibody deficiency is immunoglobulin (IG), but the care of these patients is complex. These guidelines, initiated by the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products, have been developed to facilitate and standardize the care of these patients by the various physician specialties that are responsible for their care. A panel of national expert immunologists and methodologists developed salient clinical questions; and a systematic, expert, and bibliography literature search up to July 2008 was conducted. One thousand eighty-seven citations were retrieved, and 102 reports were used in the preparation of this guideline. The recommendations provide guidance (1) on the complexity of the treatment of these patients; (2) the established benefits of IG on morbidity and mortality; (3) dosage, routes of administration, and management of reactions; (4) the various IG formulations available; (5) vaccination of these patients; and (6) research priorities.
authors: Department of Medicine, University of Toronto, Canadian Blood Services, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario, Canada. shehatan@smh.toronto.on.ca
authors: Nadine
authors: N
authors: Shehata
authors: Valerie
authors: V
authors: Palda
authors: Tom
authors: T
authors: Bowen
authors: Elie
authors: E
authors: Haddad
authors: Thomas B
authors: TB
authors: Issekutz
authors: Bruce
authors: B
authors: Mazer
authors: Robert
authors: R
authors: Schellenberg
authors: Richard
authors: R
authors: Warrington
authors: David
authors: D
authors: Easton
authors: David
authors: D
authors: Anderson
authors: Heather
authors: H
authors: Hume
mesh_terms: D002170:Canada; D019317:Evidence-Based Medicine; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy* / Q000401:mortality; D007155:Immunologic Factors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors